background
cellular
stressor
apoptosisinduc
agent
shown
induc
ribosom
rna
rrna
degrad
eukaryot
cell
recent
rna
degrad
vivo
observ
patient
local
advanc
breast
cancer
midtreat
tumor
rna
degrad
associ
complet
tumor
destruct
enhanc
patient
surviv
howev
clear
widespread
chemotherapi
induc
rna
disrupt
extent
associ
drug
respons
underli
mechan
method
ovarian
breast
cancer
cell
line
treat
sever
cytotox
chemotherapi
drug
total
rna
isol
rna
also
prepar
docetaxel
resist
carboplatin
resist
cell
follow
drug
exposur
disrupt
rna
analyz
capillari
electrophoresi
northern
blot
perform
use
probe
complementari
rrna
determin
origin
degrad
band
apoptosi
activ
assess
flow
cytometr
monitor
annexinv
propidium
iodid
pi
bind
cell
measur
activ
link
apoptosi
rna
degrad
disrupt
investig
use
inhibitor
result
chemotherapi
drug
test
capabl
induc
similar
rna
disrupt
pattern
docetaxel
treatment
resist
cell
carboplatin
treatment
cell
result
rna
disrupt
northern
blot
indic
two
rna
disrupt
band
deriv
rrna
annexinv
pi
stain
docetaxel
treat
cell
along
assess
activ
show
concurr
initi
apoptosi
rna
disrupt
inhibit
activ
significantli
reduc
rna
disrupt
conclus
support
vivo
evid
result
demonstr
rna
disrupt
induc
multipl
chemotherapi
agent
cell
line
differ
tissu
associ
drug
respons
although
present
link
apoptosi
rna
disrupt
complet
understood
evalu
rna
disrupt
thu
propos
novel
effect
biomark
assess
respons
chemotherapi
drug
vitro
vivo
control
cellular
rna
degrad
rna
molecul
play
critic
role
cell
includ
facilit
protein
synthesi
regul
gene
express
prevent
error
biosynthesi
function
cellular
rna
qualiti
control
surveil
mechan
evolv
identifi
preferenti
degrad
aberr
nonfunct
rna
degrad
nonfunct
rna
occur
regul
stage
involv
special
mechan
mechan
control
rna
degrad
exist
messeng
rna
mrna
transfer
rna
trna
ribosom
rna
rrna
activ
compon
rna
degrad
mechan
typic
includ
rnadegrad
enzym
rnase
interact
numer
cofactor
helicas
polymeras
ubiquitylas
chaperon
protein
provid
specif
type
process
degrad
dna
internucleosom
fragment
wellknown
hallmark
apoptosi
although
wellcharacter
numer
studi
shown
rrna
may
also
degrad
conjunct
apoptosi
specifics
fragment
deriv
andor
rrna
earli
studi
demonstr
cytotox
apoptosisinduc
agent
induc
rrna
fragment
apoptosi
varieti
cell
line
type
phenomenon
widespread
also
occur
plant
like
oat
mroczek
kufel
use
term
stressinduc
rrna
fragment
describ
phenomenon
variou
cellular
stressor
activ
program
cell
death
pathway
yeast
associ
rrna
degrad
howev
appar
connect
apoptosi
rrna
degrad
compulsori
shown
rrna
cleavag
could
occur
absenc
caspaseand
depend
apoptosi
although
apoptosisinduc
agent
shown
induc
rrna
degrad
mammalian
cell
cytotox
agent
chemotherapi
drug
yet
investig
respect
recent
imageguid
tumor
core
biopsi
taken
patient
local
advanc
inflammatori
breast
cancer
enrol
clinic
trial
sampl
taken
prior
posttreat
epirubicindocetaxel
combin
chemotherapi
tumor
level
sever
biomark
includ
rna
assess
relationship
treatment
respons
interestingli
signific
associ
observ
midtreat
rna
degrad
absenc
tumor
cell
breast
axilla
treatment
patholog
complet
respons
rna
degrad
band
gener
high
molecular
weight
consider
greater
observ
autolyt
degrad
rna
tissu
sampl
high
molecular
weight
band
observ
follow
week
chemotherapi
treatment
refer
abil
chemotherapi
agent
induc
longliv
rrna
fragment
typic
seen
extens
autolyt
degrad
rna
disrupt
sinc
rin
algorithm
specif
quantifi
format
low
molecular
weight
autolyt
rna
degrad
product
sinc
abnorm
rna
band
pattern
rna
disrupt
result
assign
na
valu
rin
agil
bioanalyz
recent
develop
rna
disrupt
assay
rda
quantifi
rna
disrupt
tumor
tumor
cell
rna
disrupt
index
rdi
ratio
abnorm
normal
rrna
chemotherapi
treatment
clinic
trial
also
found
associ
reduc
tumor
rna
content
patient
may
attribut
observ
rna
degrad
suppress
rna
synthesi
tumor
cell
moreov
studi
demonstr
high
tumor
rna
disrupt
midtreat
associ
markedli
enhanc
diseasefre
surviv
postchemotherapi
observ
reduc
rna
content
patient
tumor
upon
chemotherapi
treatment
also
consist
previous
publish
studi
indic
numer
cytotox
chemotherapeut
drug
strongli
interfer
ribosom
biogenesi
current
studi
describ
first
time
vitro
cell
model
system
studi
chemotherapydepend
rna
disrupt
includ
investig
relationship
rna
disrupt
drug
type
drug
dose
drug
incub
time
also
examin
whether
rna
disrupt
reflect
sensit
cell
variou
drug
previous
measur
use
clonogen
assay
addit
explor
origin
rrna
fragment
tempor
relationship
induct
apoptosi
docetaxel
measur
enhanc
caspas
activ
annexin
v
stain
rna
disrupt
final
show
inhibit
activ
reduc
elimin
rna
disrupt
respons
docetaxel
studi
requir
ethic
approv
ethic
review
committe
board
studi
involv
anim
human
human
data
materi
directli
collect
human
anim
parent
cell
line
acquir
european
collect
cell
cultur
develop
character
docetaxelresist
carboplatinresist
cell
line
use
studi
describ
previous
cell
line
maintain
cultur
medium
contain
fb
penicillin
unitsml
streptomycin
hyclon
laboratori
logan
ut
usa
docetaxel
resist
cell
line
maintain
treat
cell
docetaxel
complet
medium
weekli
carboplatin
resist
cell
similarli
maintain
treat
cell
carboplatin
cell
line
gift
dr
linda
malka
maintain
dmem
contain
fb
penicillin
unitsml
streptomycin
hyclon
laboratori
logan
ut
usa
cell
line
gift
dr
robert
lafreni
also
maintain
dmem
contain
fb
penicillin
unitsml
streptomycin
hyclon
laboratori
logan
ut
usa
cell
line
purchas
american
type
cultur
collect
manassa
va
usa
maintain
rpmi
contain
fb
penicillin
unitsml
streptomycin
hyclon
laboratori
logan
ut
usa
chemotherapi
drug
docetaxel
paclitaxel
carboplatin
cisplatin
vincristin
etoposid
irinotecan
doxorubicin
acquir
pharmaci
health
scienc
north
sudburi
ontario
canada
assess
effect
drug
dose
rna
disrupt
cell
seed
sixwel
plate
h
follow
well
expos
increas
dose
paclitaxel
docetaxel
carboplatin
determin
effect
dose
induc
rna
disrupt
time
exposur
experi
perform
cell
cultur
expos
specif
drug
dose
vari
amount
time
eg
h
replic
experi
perform
least
three
time
cell
harvest
scrape
adher
cell
lysi
buffer
collect
along
float
cell
centrifug
total
rna
isol
harvest
cell
use
mirneasi
kit
qiagen
inc
toronto
ca
quantiti
integr
isol
rna
determin
capillari
electrophoresi
agil
bioanalyz
agil
technolog
canada
inc
mississauga
ca
known
refer
rna
standard
variou
mass
rna
disrupt
index
rdi
calcul
sampl
use
proprietari
algorithm
rna
diagnost
inc
toronto
ca
comput
ratio
abnorm
normal
rrna
total
rna
isol
cell
treat
without
docetaxel
h
compon
rna
per
lane
resolv
denatur
formaldehyd
agaros
gel
electrophoresi
transfer
biotrac
pvdf
membran
life
scienc
pensacola
fl
usa
uv
crosslink
membran
incub
variou
radiolabel
probe
hybrid
sequenc
within
rrna
probe
tabl
deriv
rrna
probe
describ
public
et
al
houg
et
al
nadano
et
al
align
probe
sequenc
check
human
rrna
sequenc
rrna
genbank
id
rrna
genbank
id
ensur
complet
sequenc
homolog
probe
label
use
patp
dna
end
label
system
promega
fisher
scientif
mississauga
ca
hybrid
perform
accord
brown
mackey
follow
hybrid
wash
blot
seal
bag
expos
phosphor
imag
screen
variou
length
time
screen
scan
use
biorad
molecular
imag
fx
biorad
laboratori
ltd
mississauga
ca
band
size
determin
use
quantiti
one
softwar
biorad
laboratori
inc
analyz
effect
docetaxel
proport
cell
enter
apoptosi
cell
stain
annexin
v
propidium
iodid
pi
cytoglo
annexin
vftic
apoptosi
kit
imgenex
san
diego
ca
usa
percentag
apoptot
cell
annexin
v
posit
pi
neg
determin
flow
cytometri
bd
fac
canto
ii
flow
cytomet
bectondickinson
bioscienc
mississauga
ca
effect
docetaxel
cell
cycl
progress
also
assess
flow
cytometri
cell
fix
stain
pi
alon
describ
previous
activ
extract
control
docetaxeltr
cell
assay
monitor
cleavag
devd
substrat
use
colorimetr
assay
kit
biovis
inc
milpita
ca
usa
effect
inhibit
docetaxelinduc
caspas
activ
docetaxeldepend
rna
disrupt
determin
treat
cell
without
docetaxel
andor
inhibitor
qdevdoph
biovis
inc
milpita
ca
usa
assay
extract
cell
activ
rna
disrupt
describ
statist
analys
perform
use
microsoft
excel
graphpad
prism
softwar
differ
p
consid
statist
signific
signific
determin
use
twoway
anova
bonferroni
posthoc
test
compar
two
variabl
onetail
ttest
perform
determin
impact
increas
carboplatin
concentr
cellular
rdi
valu
data
twotail
ttest
perform
applic
ftest
determin
equal
varianc
taxaneinduc
rna
disrupt
cell
doseand
timedepend
rna
disrupt
cell
cultur
becam
evid
dose
docetaxel
paclitaxel
peak
drug
respect
rna
disrupt
evid
taxanetr
cell
presenc
abnorm
band
electropherogram
distinct
normal
rna
band
pattern
seen
untreat
cell
fig
c
furthermor
signific
decreas
total
cellular
rna
content
also
observ
upon
chemotherapi
treatment
addit
file
investig
effect
time
rna
disrupt
cell
treat
paclitaxel
docetaxel
h
fig
c
rna
disrupt
becam
detect
h
continu
increas
h
rdi
valu
confirm
signific
increas
rna
disrupt
paclitaxeland
docetaxeltr
sampl
time
fig
untreat
control
sampl
exhibit
abnorm
band
electropherogram
retain
low
rdi
valu
time
point
ovarian
carcinoma
cell
line
also
treat
docetaxel
determin
ovarian
cancer
cell
line
could
exhibit
taxaneinduc
rna
disrupt
use
docetaxel
dose
cell
rna
disrupt
observ
cell
carboplatin
structur
distinct
drug
differ
mechan
action
taxan
requir
longer
exposur
time
induc
rna
disrupt
cell
therefor
cell
treat
h
increas
dose
carboplatin
figur
b
display
rna
electropherogram
rdi
valu
cell
treat
carboplatin
cell
rna
disrupt
becam
detect
significantli
higher
begin
carboplatin
cell
rna
disrupt
detect
carboplatin
rdi
valu
becom
significantli
higher
compar
untreat
cell
carboplatin
use
fig
acg
tgt
tag
act
cct
tgg
tcc
abnorm
rna
disrupt
band
occur
upon
chemotherapi
drug
exposur
smaller
molecular
weight
andor
rrna
determin
whether
abnorm
band
origin
andor
rrna
northern
blot
experi
perform
total
rna
prepar
cell
incub
absenc
presenc
docetaxel
h
fig
probe
complementari
rrna
probe
hybrid
rna
disrupt
band
fig
addit
file
figur
show
hybrid
probe
rrna
two
smaller
band
comput
nt
nt
length
rna
disrupt
band
deriv
rrna
sequenc
given
locat
probe
bind
within
rrna
see
discuss
diagram
rrna
fig
indic
deriv
nt
nt
band
upon
rna
disrupt
three
probe
use
attempt
detect
fragment
deriv
rrna
none
probe
abl
detect
fragment
rrna
h
docetaxel
treatment
addit
file
investig
relationship
drug
sensit
druginduc
rna
disrupt
total
rna
isol
docetaxelsensit
docetaxelresist
cell
treatment
docetaxel
h
consist
known
drug
sensit
use
clonogen
assay
cell
exhibit
significantli
higher
rna
disrupt
index
cell
fig
use
rdi
analysi
abl
confirm
respons
significantli
higher
rdi
valu
observ
treat
resist
cell
compar
untreat
resist
cell
demonstr
sensit
cell
carboplatin
cell
docetaxel
fig
rda
consist
reflect
differenti
drug
sensit
display
higher
rdi
valu
rna
disrupt
band
drugsensit
cell
addit
file
b
c
assess
whether
docetaxel
induc
apoptosi
whether
concurr
induct
rna
disrupt
cell
treat
docetaxel
vari
time
h
cell
stain
annexin
vfluorescein
isothiocyan
annexin
vfitc
propidium
iodid
pi
analyz
flow
cytometri
fig
wakeman
et
al
locat
probe
rrna
sequenc
shown
diagram
use
arrow
locat
cleavag
site
result
band
shown
diagram
increas
number
cell
stain
annexin
vfitc
persist
h
indic
cell
earli
apoptosi
increas
pi
stain
observ
h
suggest
cell
retain
plasma
membran
integr
undergon
necrosi
next
effect
docetaxel
treatment
cell
cycl
progress
investig
use
pi
stain
fix
cell
follow
h
docetaxel
exposur
fig
sub
g
peak
often
associ
apoptot
bodi
evid
docetaxel
treat
cell
h
h
almost
pi
signal
sub
g
peak
show
extend
docetaxel
treatment
gener
cell
fragment
less
diploid
amount
dna
content
repres
apoptot
bodi
micronuclei
final
see
dna
ladder
late
apoptosi
biomark
also
occur
jurkat
cell
treat
without
docetaxel
cell
etoposid
jurkat
cell
similar
length
time
genom
dna
prepar
cell
resolv
agaros
gel
electrophoresi
fig
interestingli
docetaxeltr
cell
show
evid
dna
fragment
dna
etoposidetr
jurkat
cell
clearli
degrad
confirm
cell
treat
docetaxel
longer
viabl
despit
lack
dna
degrad
recoveri
assay
perform
determin
docetaxeltr
cell
capabl
resum
growth
transfer
drugfre
cell
cultur
medium
follow
exposur
docetaxel
h
cell
replat
fresh
drugfre
medium
cultur
addit
hour
fig
cell
treat
docetaxel
never
recov
regardless
incub
time
treat
docetaxel
could
recov
h
docetaxel
exposur
h
docetaxel
exposur
one
relat
observ
extent
rna
disrupt
induc
cell
treat
docetaxel
time
fig
appear
cell
toler
specif
level
rna
disrupt
rdi
cell
becom
nonviabl
support
induct
apoptosi
cell
respons
docetaxel
examin
effect
docetaxel
treatment
activ
h
follow
treatment
figur
show
activ
increas
respons
docetaxel
h
respons
persist
h
possibl
connect
docetaxelinduc
activ
rna
disrupt
investig
treat
cell
docetaxel
absenc
presenc
inhibitor
qdevdoph
shown
fig
suppress
activ
qdevdoph
evid
begin
h
cotreat
docetaxel
statist
signific
reduct
activ
appar
h
fig
previou
studi
shown
varieti
apoptosisinduc
agent
distinct
mechan
action
glucocorticoid
okada
acid
tumor
necrosi
factor
tnf
dexamethason
calcium
ionophor
tricothecen
mycotoxin
abl
induc
order
apoptosisassoci
rrna
degrad
sever
differ
cell
type
includ
plant
cell
unicellular
organ
yeast
howev
studi
first
report
abil
structur
distinct
cytotox
chemotherapi
agent
differ
mechan
action
induc
format
high
molecular
weight
rrna
degrad
fragment
fig
phenomenon
term
rna
disrupt
suggest
despit
contrast
structur
mechan
action
differ
chemotherapi
agent
activ
common
rrna
degrad
mechan
moreov
chemotherapi
induc
rna
disrupt
observ
across
multipl
ovarian
breast
cancer
cell
line
support
widespread
natur
phenomenon
fig
observ
rna
disrupt
doseand
timedepend
fig
moreov
extent
rna
disrupt
close
reflect
cellular
sensit
chemotherapi
agent
fig
rna
disrupt
observ
occur
cell
line
demonstr
sensit
chemotherapi
agent
measur
use
clonogen
assay
rna
disrupt
observ
deriv
cell
line
exhibit
resist
agent
fig
also
show
studi
tempor
relationship
induct
apoptosi
docetaxel
cell
rna
disrupt
agent
signific
rna
disrupt
occur
h
exposur
paclitaxel
docetaxel
cell
h
ovarian
tumor
cell
line
treat
docetaxel
rna
disrupt
alway
maxim
longest
incub
time
h
fig
carboplatininduc
rna
disrupt
requir
longer
exposur
time
detect
h
rdi
valu
carboplatintr
cell
significantli
differ
untreat
cell
drug
concentr
appli
cell
fig
differ
exposur
time
concentr
need
induc
rna
disrupt
may
due
differ
mechan
action
two
drug
furthermor
drug
produc
slightli
differ
rrna
fragment
rrna
band
fig
although
common
rrna
fragment
slightli
greater
mobil
rrna
gener
agent
differ
rna
fragment
pattern
observ
houg
et
al
depend
upon
apoptosisinduc
agent
use
cell
line
investig
observ
uniqu
cleavag
site
rrna
bovin
endotheli
cell
although
rna
cleavag
pattern
differ
cell
type
remark
similar
overal
yeast
differ
apoptosisinduc
agent
treatment
also
gener
differ
pattern
rrna
degrad
anoth
studi
et
al
murin
macrophag
rrna
cleavag
induc
tricothecen
mycotoxin
deoxynivalenol
pattern
observ
et
al
contain
similar
fragment
rrna
contain
three
fragment
region
rrna
bandssimilar
pattern
observ
houg
et
al
studi
nadano
et
al
two
differ
apoptosisinduc
agent
use
jurkat
cell
initi
rrna
fragment
fa
ligand
produc
pattern
band
rrna
one
clearli
discern
band
region
rrna
differ
rna
band
pattern
demonstr
king
et
al
cell
treat
sever
differ
apoptot
stimuli
degrad
band
rrna
observ
degrad
band
deriv
rrna
studi
rna
disrupt
pattern
gener
taxan
treatment
cell
compos
major
fragment
rrna
band
two
major
fragment
rrna
band
fig
carboplatin
treatment
also
gener
fragment
rrna
band
cell
appear
gener
multipl
fragment
region
rrna
fig
therefor
order
rna
disrupt
appear
occur
differ
way
depend
cell
type
stimulu
suggest
vari
mechan
reaction
kinet
rna
disrupt
cell
depend
upon
cell
line
andor
rna
disruptioninduc
agent
studi
document
abil
specif
chemotherapi
agent
induc
cell
death
growth
arrest
clonogen
assay
also
reflect
abil
induc
rna
disrupt
tumor
cell
vitro
fig
data
thu
suggest
rna
disrupt
chemotherapi
agent
accur
reflect
cellular
drug
sensit
drug
resist
measur
use
highli
sensit
clonogen
assay
reinforc
use
rna
disrupt
assay
rda
techniqu
quantifi
respons
cytotox
agent
chemotherapi
drug
moreov
rna
disrupt
assay
appear
equival
sensit
clonogen
assay
evalu
respons
treatment
much
less
labor
intens
amen
high
throughput
approach
requir
less
time
obtain
assay
result
may
thu
repres
valuabl
tool
drug
discoveri
observ
current
studi
see
figur
previou
page
fig
recoveri
prolifer
cell
follow
docetaxel
treatment
order
assess
whether
cell
treat
docetaxel
dxl
show
rna
degrad
abl
recov
prolifer
cell
treat
docetaxel
h
follow
treatment
end
point
cell
collect
replat
fresh
drugfre
medium
prolifer
assess
follow
recoveri
h
replat
recoveri
cell
h
treatment
b
recoveri
h
drug
treatment
c
recoveri
follow
h
drug
treatment
also
provid
vitro
confirm
associ
rna
disrupt
respons
chemotherapi
patient
local
advanc
breast
cancer
northern
blot
total
rna
isol
cell
treat
docetaxel
use
identifi
approxim
origin
rna
disrupt
band
describ
probe
hybrid
fulllength
rrna
two
rrna
fragmentson
migrat
faster
fulllength
rrna
nt
one
migrat
intact
nt
rrna
band
fig
size
determin
nt
nt
respect
although
calcul
size
interpret
approxim
valu
sinc
fragment
detect
probe
must
deriv
rrna
smaller
fragment
deriv
larger
fig
size
nt
larger
fragment
suggest
must
cleavag
site
within
fulllength
rrna
sequenc
approxim
nt
end
molecul
minu
nt
smaller
fragment
nt
indic
anoth
cleavag
site
locat
nt
end
molecul
minu
nt
see
fig
interpret
suggest
anoth
rrna
fragment
nt
produc
upon
docetaxel
treatment
nucleotid
molecul
detect
probe
reason
clear
possibl
nt
fragment
gener
stabl
andor
subject
immedi
rnase
digest
support
idea
mroczek
kufel
report
rrna
fragment
suscept
digest
exosom
fragment
cleavag
site
nt
end
rrna
locat
variabl
region
expans
segment
identifi
contain
rnase
cleavag
site
prior
studi
nucleotid
sequenc
variabl
region
correl
wakeman
et
al
structur
featur
human
rrna
base
analysi
doubl
loop
structur
end
rrna
contain
cleavag
site
identifi
et
al
houg
et
al
locat
second
loop
variabl
expans
region
estim
cleavag
site
rrna
data
also
locat
loop
support
identif
locat
import
site
vulner
cleavag
respons
variou
cytotox
stressor
studi
fragment
deriv
rrna
detect
use
three
differ
probe
recogn
rrna
sequenc
addit
file
indic
rrna
cleav
within
h
period
exposur
docetaxel
lack
cleavag
rrna
report
sever
studi
other
show
cleavag
rrna
differ
origin
rna
disrupt
band
may
relat
agentstressor
induc
rrna
degrad
andor
time
incub
exampl
observ
loss
rrna
band
rna
electropherogram
cell
incub
taxan
especi
later
time
point
h
fig
c
degrad
rrna
cytotox
stressor
shown
correl
induct
apoptosi
sever
cell
system
current
studi
chemotherapi
drug
docetaxel
appear
induc
apoptosi
cell
evidenc
elev
annexin
v
bind
peak
h
fig
increas
activ
peak
h
fig
dramat
rise
amount
apoptot
bodi
subg
dna
content
peak
h
fig
rna
disrupt
also
induc
docetaxel
cell
highest
h
studi
fig
suggest
tempor
correl
induct
apoptosi
rna
disrupt
associ
rna
disrupt
apoptosi
also
suggest
find
cell
permeabl
caspas
inhibitor
qdevdoph
abl
partial
suppress
activ
docetaxelinduc
rna
disrupt
fig
c
consist
previou
find
apoptosi
associ
rrna
degrad
depend
upon
caspas
activ
howev
apoptosi
occur
without
rna
disrupt
rrna
cleavag
observ
absenc
caspaseand
depend
apoptosi
suggest
two
process
occur
independ
moreov
increas
evid
caspas
may
play
role
cell
cycl
progress
independ
role
promot
cell
death
similarli
role
caspas
rna
disrupt
may
unrel
role
apoptosi
result
also
show
docetaxel
treatment
cell
promot
dna
ladder
fig
common
phenomenon
associ
apoptosi
mani
cell
type
howev
lack
dna
degrad
apoptosi
report
number
studi
find
suggest
docetaxelinduc
apoptosi
cell
lack
mechan
activ
dna
fragment
rna
fragment
mechan
block
also
worth
note
addit
studi
laboratori
indic
apoptot
biomark
cleav
parp
cleavag
wane
consider
h
addit
file
rna
disrupt
product
persist
fig
rna
disrupt
may
thu
prefer
biomark
identifi
cellstissuespati
respond
chemotherapi
present
mechan
chemotherapydepend
rna
disrupt
unknown
mechan
rrna
degrad
induc
nutrit
deficit
call
ribophagi
describ
shown
distinct
gener
autophagi
specif
ubiquitin
deubiquitin
protect
promot
ribophagi
indic
import
role
ubiquitin
statu
ribosom
determin
suscept
ribophagi
howev
chemotherapi
druginduc
rrna
disrupt
occur
without
known
nutrit
deficit
irrevers
suffici
rrna
disrupt
occur
ribophagi
appear
promot
surviv
extend
nutrit
depriv
second
mechan
select
remov
nonfunct
ribosom
nonfunct
rrna
decay
nrd
also
describ
ubiquitin
also
play
role
nrd
differ
protein
involv
ribophagi
appear
involv
includ
factor
known
act
dna
repair
rule
either
ribophagi
nrd
time
mechan
ribosom
decay
contribut
rrna
disrupt
worth
note
gener
specif
high
molecular
weight
rrna
fragment
yet
report
associ
either
ribophagi
nrd
anoth
possibl
mechan
may
involv
recent
describ
abil
chemotherapi
agent
docetaxel
doxorubicin
induc
product
releas
tumor
cell
could
turn
result
activ
specif
receptor
known
induc
apoptosi
activ
specif
caspas
consist
view
fa
ligand
shown
induc
rrna
degrad
human
leukemia
cell
furthermor
chemotherapi
agent
docetaxel
doxorubicin
also
well
known
induc
reactiv
oxygen
speci
ro
tumor
cell
turn
activ
caspas
andor
apoptosi
ro
directli
promot
phosphoryl
ubiquitin
famili
protein
result
cytochrom
c
releas
mitochondria
caspas
activ
mitochondria
appear
sourc
target
ro
inde
mroczek
kufel
present
strong
evid
apoptosisassoci
rrna
fragment
yeast
correl
ro
level
cellular
respons
oxid
stress
reduc
mitochondri
activ
caspas
activ
tumor
cell
mechan
could
differ
somewhat
consid
caspas
could
activ
ro
gener
result
rna
disrupt
evid
provid
current
studi
demonstr
caspas
inhibitor
significantli
reduc
docetaxelinduc
rna
disrupt
term
possibl
enzym
facilit
rna
disrupt
highli
like
rna
hydrolas
rnase
rnase
could
homolog
rnase
recent
identifi
play
role
stressinduc
rrna
degrad
yeast
investig
identifi
sever
rnase
associ
stressinduc
rrna
fragment
yeast
mammalian
homolog
would
exonucleas
endonucleas
involv
rrna
process
mrp
rnase
associ
nuclear
cytoplasm
human
exosom
mitochondri
nucleas
endonucleas
g
studi
plan
elucid
precis
mechan
involv
rna
disrupt
cytotox
chemotherapi
drug
studi
show
rna
disrupt
induc
variou
cell
type
structur
distinct
chemotherapi
agent
contrast
mechan
action
doseand
timedepend
manner
disrupt
fragment
least
docetaxel
initi
stem
cleavag
within
expans
segment
variabl
region
rrna
extent
rna
disrupt
observ
cell
reflect
sensit
lack
thereof
chemotherapi
drug
cell
toler
specif
level
rna
disrupt
becom
nonviabl
moreov
induct
rna
disrupt
tempor
correl
induct
apoptosi
rna
fragment
product
accumul
time
apoptot
biomark
wane
rna
disrupt
associ
caspas
activ
known
inhibitor
substanti
reduc
rna
disrupt
docetaxel
link
drug
sensit
cell
line
previous
assess
clonogen
assay
druginduc
rna
disrupt
strongli
support
recent
clinic
find
high
tumor
rna
disrupt
associ
tumor
sensit
drug
express
patholog
complet
respons
enhanc
diseasefre
surviv
neoadjuv
chemotherapi
patient
local
advanc
inflammatori
breast
cancer
rna
disrupt
thu
appear
highli
reproduc
natur
phenomenon
observ
tumor
cell
repres
power
new
vitro
vivo
biomark
chemotherapi
respons
addit
file
chang
total
rna
concentr
result
paclitaxel
treatment
total
rna
isol
cell
treat
paclitaxel
h
assess
chang
quantiti
well
integr
addit
presenc
uniqu
band
signific
decreas
rna
concentr
observ
result
drug
treatment
appear
dose
timedepend
